The financial architecture of cancer care is reaching a critical inflection point as we move through the 2026 fiscal year. According to the latest Oncology Drugs Market Data, the sector is experiencing a unique "price-volume" paradox; while the cost of developing cutting-edge therapies like CRISPR-based cell edits remains high, the entry of aggressive biosimilar competition is driving...